<h2>Objective</h2>
To compare the effectiveness of&nbsp;iGlarLixi&nbsp;with&nbsp;BI+RAI&nbsp;in people with T2D advancing from BI therapy using real-world evidence

References

<h2>Study Design</h2>
To compare the effectiveness of&nbsp;iGlarLixi&nbsp;with&nbsp;BI+RAI&nbsp;in people with T2D advancing from BI therapy using real-world evidence 
 Retrospective, observational, cohort study of anonymized patient data collected from the OMOP US Ambulatory EMRs database 
 POPULATION
<ul>
 <li>≥18 years old with T2D</li>
 <li>At least one prescription of BI within the baseline period</li>
 <li>Valid HbA1c and body weight values during baseline and post-index period</li>
</ul>
Participants matched to&nbsp;iGlarLixi&nbsp;and&nbsp;BI+RAI&nbsp;groups 1:1 using propensity score matching

Abbreviations

<h2>Study endpoints</h2>
<h3>Primary Endpoints</h3>
Non-inferiority of&nbsp;iGlarLixi&nbsp;vs&nbsp;BI+RAI&nbsp;in HbA1c&nbsp;change from baseline to 6 months (non-inferiority margin 0.3 %)*
<h3>Secondary Endpoints</h3>
Superiority of&nbsp;iGlarLixi&nbsp;vs&nbsp;BI+RAI&nbsp;in:†
<ol>
 <li>Change in body weight from baseline to 6 months</li>
 <li>Composite target achievement of HbA1c &lt;7 % (&lt;53 mmol/mol) without any hypoglycemia‡ and without any body weight gain at 6 months</li>
 <li>Change in HbA1c&nbsp;from baseline to 6 months</li>
</ol>

<h3>Additional Endpoints</h3>
<ul>
 <li>Hypoglycemia incidence and event rate at 6-month follow-up</li>
 <li>Subgroup analysis in participants with baseline age ≥65 years and HbA1c ≥9 % (≥75 mmol/mol)</li>
</ul>
*The primary endpoint of between-treatment difference in mean HbA1c change was assessed using a paired t-test (one-sided, α=0.025), with a non-inferiority margin of 0.3 % (3 mmol/mol); †Key secondary endpoints were assessed in hierarchical order (to control overall type I error) to demonstrate superiority of iGlarLixi vs BI+RAI in 1) body weight change; 2) composite target achievement; and 3) HbA1c change (two-sided, α=0.05). Paired t-tests were used to compare between-treatment differences in body weight while the odds ratio of participants reaching the composite target endpoint between treatment cohorts was estimated by logistic regression: ‡Defined as ICD-10-CM code E16.2 and SNOMED code 4154498, or blood glucose &lt;70 mg/dL [&lt;3.9 mmol/L]) confirmed either by laboratory testing or observation results 
 BI, basal insulin; ICD-10-CM, International Classification of Diseases-10 Clinical Modification; iGlarLixi, insulin glargine 100 U/mL and lixisenatide; RAI, rapid-acting insulin; SNOMED, Systemized Nomenclature of Medicine

<h2>Baseline characteristics after propensity score matching (PSM)</h2>

<table border="1" cellpadding="1" cellspacing="1" style="width:100%;">
 <thead>
 <tr>
 <th scope="col">&nbsp;</th>
 <th scope="col">iGlarLixi (N=814)</th>
 <th scope="col">BI+RAI (N=814)</th>
 <th scope="col">STD DIFF</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td style="background-color: rgb(244, 242, 246);">Age at index, years, mean ±&nbsp;SD</td>
 <td style="text-align: center;">61.5&nbsp;± 11.0</td>
 <td style="background-color: rgb(244, 242, 246); text-align: center;">61.6&nbsp;± 11.1</td>
 <td style="text-align: center;">0.01</td>
 </tr>
 <tr>
 <td style="background-color: rgb(244, 242, 246);">Sex, female, n(%)</td>
 <td style="text-align: center;">392 (48.2)</td>
 <td style="background-color: rgb(244, 242, 246); text-align: center;">400 (49.1)</td>
 <td style="text-align: center;">0.02</td>
 </tr>
 <tr>
 <td style="background-color: rgb(244, 242, 246);">Body weight, kg, mean&nbsp;± SD</td>
 <td style="text-align: center;">100.1&nbsp;± 22.7</td>
 <td style="background-color: rgb(244, 242, 246); text-align: center;">99.0&nbsp;± 23.5</td>
 <td style="text-align: center;">0.04</td>
 </tr>
 <tr>
 <td style="background-color: rgb(244, 242, 246);">HbA1c,&nbsp;mean&nbsp;± SD*, % (mmol/mol)</td>
 <td style="text-align: center;">9.2&nbsp;± 1.8&nbsp; 
 (77&nbsp;± 20)</td>
 <td style="background-color: rgb(244, 242, 246); text-align: center;">9.2&nbsp;± 1.7 
 (77&nbsp;± 19)</td>
 <td style="text-align: center;">0.01</td>
 </tr>
 </tbody>
</table>

PSM generated cohorts with balanced baseline characteristics Participants had high baseline HbA1c and a large proportion had comorbidities
*Closest to index date; †Balance between PSM groups assessed using STDDIFF and a threshold of 0.1

Primary outcome
<ul>
 <li>Both&nbsp;iGlarLixi&nbsp;and&nbsp;BI+RAI&nbsp;improved overall glycemic control</li>
 <li>iGlarLixi&nbsp;was non-inferior to&nbsp;BI+RAI&nbsp;in change in HbA1c from baseline to month 6</li>
</ul>

*one-sided p-value assessing non-inferiority of iGlarLixi vs BI+RAI with non-inferiority margin = 0.3 % (3 mmol/mol); †GlarLixi mmol/mol values were 77 ± 20 at baseline and 69 ± 19 at follow-up; ‡BI+RAI mmol/mol values were 77 ± 19 at baseline and 68 ± 19 at follow-up

<h2>Secondary outcomes</h2>
<h3 style="text-align: center;">Mean body weight change</h3>

Superiority of&nbsp;iGlarLixi&nbsp;vs&nbsp;BI+RAI&nbsp;in body weight change from baseline to 6 months was achieved
<h3 style="text-align: center;">HbA1c&nbsp;&lt;7 % without hypoglycemia and weight gain*</h3>

As superiority of&nbsp;iGlarLixi&nbsp;vs&nbsp;BI+RAI&nbsp;for composite endpoint achievement was not reached, superiority in HbA1c&nbsp;change was not tested
*proportion of participants achieving HbA1c &lt;7 % (&lt;53 mmol/mol) without any hypoglycemia and without body weight gain at 6-month follow-up; †two-sided p-value assessing superiority of iGlarLixi vs BI+RAI

<h2>Other Outcomes</h2>
At 6-month follow-up, there were very few hypoglycemia events recorded for either treatment group, likely due to underreporting, and no significant between-treatment differences were seen in incidence or rates Sensitivity analyses&nbsp;showed similar results*

Participants ≥65 years
<ul>
 <li>Mean HbA1c&nbsp;from baseline to 6-month were similar for&nbsp;iGlarLixi&nbsp;and&nbsp;BI+RAI, and comparable in magnitude to overall population</li>
 <li>HbA1c&nbsp;&lt;7 % (&lt;53 mmol/mol) without hypoglycemia or body weight gain was achieved by 11.6% and 7.7% participants treated with&nbsp;iGlarLixi&nbsp;and&nbsp;BI+RAI, respectively</li>
</ul>

Participants with baseline HbA1c ≥9 % (≥75 mmol/mol)
<ul>
 <li>iGlarLixi&nbsp;and&nbsp;BI+RAI&nbsp;were associated with similar HbA1c reductions from baseline to 6-months</li>
 <li>HbA1c&nbsp;target &lt;7 % (&lt;53 mmol/mol) without hypoglycemia or body weight gain was achieved by ~5.0% of participants with both&nbsp;iGlarLixi&nbsp;and&nbsp;BI+RAI</li>
</ul>

Subgroup analysis results reflected outcomes of the overall population
*Sensitivity analyses included: analysis of primary and key secondary endpoints in participants identified between 01 January 2017 and 30 June 2019 to assess possible impacts of COVID-19 pandemic; analysis of key primary and secondary endpoints in participants who had ≥1 additional treatment prescription within 180 days post-index date, and participants who had ≥1 treatment prescription within 120 days post-index date; the proportion of participants achieving the composite target of HbA1c &lt;8 % without any hypoglycemia and without any body weight gain

Strengths
<ul>
 <li>First study comparing&nbsp;iGlarLixi&nbsp;with a&nbsp;BI+RAI&nbsp;regimen for T2D treatment in a real-world setting</li>
 <li>Robust sensitivity analyses confirmed the main findings</li>
 <li>PSM helps reduce bias from potential confounders</li>
</ul>

Limitations
<ul>
 <li>Not a randomized controlled trial (RCT). Lack of randomization may lead to bias from unknown confounders</li>
 <li>Risk of selection bias, e.g. HCP choices of prescribing different regimens</li>
 <li>Levels of treatment adherence will likely be lower than those achieved in an RCT which could minimize between-treatment differences</li>
 <li>Risk of potential missing information in the IQVIA database, e.g. few hypoglycemia events reported</li>
</ul>

<h2>Conclusion</h2>
<ul>
 <li>iGlarLixi&nbsp;was non-inferior to&nbsp;BI+RAI&nbsp;in HbA1c reductions achieved after 6 months therapy</li>
 <li>iGlarLixi&nbsp;did not result in weight gain while weight gain was seen with&nbsp;BI+RAI</li>
 <li>Hypoglycemia was low in both&nbsp;iGlarLixi&nbsp;and&nbsp;BI+RAI&nbsp;groups, likely due to under-reporting, with no between-treatment differences observed</li>
 <li>The present RWE results support evidence from the DUAL VII RCT comparing an FRC with a&nbsp;BI+RAI&nbsp;regimen1</li>
 <li>RWE shows&nbsp;iGlarLixi&nbsp;provides similar glycemic outcomes to&nbsp;BI+RAI&nbsp;after 6 months, with the added benefit of less weight gain and a simpler regimen</li>
</ul>

IGlarLixi vs basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify real-world study

TYPE-2-DIABETES

DIABETES

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.